News & Trends - Pharmaceuticals

BMS announces new 5-year data in advanced renal cell carcinoma

Health Industry Hub | February 19, 2020 |
[Total: 1    Average: 5/5]

Pharma News: Bristol-Myers Squibb announced five-year follow-up study results demonstrating that Opdivo (nivolumab) treatment delivers superior overall survival (OS) and objective response rates (ORR) in patients with previously treated advanced or metastatic renal cell carcinoma (RCC) compared to those treated with Novartis’ everolimus. 

With an extended minimum follow-up of 64 months, patients treated with Opdivo in the phase III CheckMate -025 study continue to demonstrate OS benefit with 26% of patients alive compared to 18% of patients treated with everolimus. Additionally, the percentage of patients experiencing an objective response was 23% for Opdivo versus 4% for everolimus and the median duration of response (mDOR) for Opdivo was also maintained longer than for everolimus (18.2 months vs. 14 months, respectively).

The overall safety profile was consistent with that observed in previously reported analyses from CheckMate -025 in patients with RCC. No new safety signals or drug-related deaths occurred with extended follow-up.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture measure up in the industry, according to results from employee feedback? Get the benchmark analysis by contacting us.

“Five-year survival results from the CheckMate -025 study, along with the ongoing response rates observed in the trial, highlight the potential for long-term survival and efficacy of nivolumab monotherapy for patients with previously-treated advanced RCC,” said lead investigator Robert J. Motzer, MD, Kidney Cancer Section Head, Memorial Sloan Kettering Cancer Center. “These data represent the longest follow-up for a PD-1 immune checkpoint inhibitor in this setting and underscore the potential increased survival rates nivolumab can deliver for patients with advanced RCC who have received prior antiangiogenic therapy.”

“The updated CheckMate -025 results support why Opdivo monotherapy became a standard of care for previously treated RCC patients worldwide and offer additional evidence that treatment with Opdivo has the potential to help patients live longer,” said Brian Lamon, Ph.D., development lead, genitourinary cancers, Bristol-Myers Squibb. “This study represents exciting progress in our mission to improve survival outcomes for all patients.”

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech news - New 5 minute coronavirus test delivers clear results on infection

New 5 minute coronavirus test delivers clear results on infection

Health Industry Hub | April 9, 2020 |

A new type of sensor device from the German health technology company Digital Diagnostics AG can be used for immediate […]

More


Marketing & Strategy

Marketing & Strategy in Healthcare - Customer-Centric Engagement During COVID-19

Customer-Centric Engagement During COVID-19

Health Industry Hub | April 8, 2020 |

Navigating the multichannel maze in COVID 19 times to engage healthcare professionals (HCPs) and patients has been challenging for most […]

More


News & Trends - Medical Technology

MedTech News - Stryker launches limited-release medical bed to support critical needs during COVID-19 pandemic

Stryker launches limited-release medical bed to support critical needs during COVID-19 pandemic

Health Industry Hub | April 8, 2020 |

MedTech News: Stryker has developed a low-cost, limited-release emergency response bed to quickly aid healthcare providers with efficient care during […]

More


Medical

Medical News - AMA urges Australians to continue with ongoing medical care amid COVID-19 crisis

AMA urges Australians to continue with ongoing medical care amid COVID-19 crisis

Health Industry Hub | April 8, 2020 |

Medical News: The AMA is urging people to keep a close watch on their ongoing health care and maintenance, and […]

More